(Q51031002)

27 March 2018

title

Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial (English)

1 reference

27 March 2018

author name string

M K Wallack

1

1 reference

27 March 2018

M Sivanandham

2

1 reference

27 March 2018

B Whooley

3

1 reference

27 March 2018

K Ditaranto

4

1 reference

27 March 2018

A A Bartolucci

5

1 reference

27 March 2018

publication date

1 March 1996

1 reference

27 March 2018

Annals of Surgical Oncology

published in

1 reference

27 March 2018

volume

3

1 reference

27 March 2018

issue

2

1 reference

27 March 2018

page(s)

110-117

1 reference

27 March 2018

Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma

cites work

1 reference

12 December 2020

Active specific immunotherapy in malignant melanoma

1 reference

12 December 2020

Specific tumor immunity produced by the injection of vaccinia viral oncolysates

1 reference

12 December 2020

A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.

1 reference

12 December 2020

Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate

1 reference

12 December 2020

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

12 December 2020

A new approach in specific, active immunotherapy

1 reference

12 December 2020

Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant

1 reference

12 December 2020

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

1 reference

12 December 2020

Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma

1 reference

12 December 2020

HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy

1 reference

12 December 2020

Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells

1 reference

12 December 2020

A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates

1 reference

12 December 2020

Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma

1 reference

12 December 2020

Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases

1 reference

12 December 2020

A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment.

1 reference

12 December 2020

Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies

1 reference

12 December 2020

Serologic response to human melanoma lines from patients with melanoma undergoing treatment with vaccinia melanoma oncolysates

1 reference

12 December 2020

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

12 December 2020

Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates

1 reference

12 December 2020

Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02305788

1 reference

27 March 2018

release_qtggqsxyqregjitinxfqwysgwa

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qtggqsxyqregjitinxfqwysgwa

24 November 2022

mapped directly with Wikidata item

1 reference

27 March 2018